Trump Signs Executive Order on Psychedelic Medical Research
On Saturday, President Donald Trump signed an executive order aimed at speeding up the review process for the use of psychedelics in medical treatments, particularly for mental health issues.
The order, part of the Accelerated Medical Treatment of Serious Mental Illness Act, seeks to tackle the growing rates of suicide and severe mental illness in the U.S. It facilitates the exploration of psychedelic substances like ibogaine, which is categorized as a Schedule I drug. The order reflects concerns over the significant rise in suicide rates during the COVID-19 pandemic and amidst the Biden administration’s tenure.
“This order will finally provide those suffering from debilitating conditions a chance to reclaim their lives and pursue happiness,” Trump remarked to reporters.
Notable figures such as popular podcaster Joe Rogan and former Navy SEAL Marcus Luttrell, known for advocating the use of ivermectin against the coronavirus, were present at the signing, alongside Trump and HHS Secretary Robert F. Kennedy Jr.
Rogan mentioned that he shared information with Trump about the remarkable effects ibogaine has had on veterans dealing with PTSD and traumatic brain injuries. He relayed that the response was enthusiastic, with Trump asking, “Great! Do you want FDA approval? Let’s do it!”
During the ceremony, Rogan highlighted the alarming figures regarding overdose deaths, predicting over 80,000 fatalities in 2024. He stated, “One dose of ibogaine can help over 80 percent of individuals break free from addiction. Two doses can increase that success rate to over 90 percent.”
The executive order instructs HHS to collaborate with the Department of Veterans Affairs and the private sector to enhance participation in clinical trials, facilitate data sharing, and gather real-world evidence on the application of psychedelics.
The second section of the order empowers the Food and Drug Administration to extend the “right to try” provision to hallucinogens, allowing eligible individuals with specific diagnoses to access these treatments.
According to the order, clinical studies indicate that psychedelic substances, including ibogaine, show promise in treating severe mental health conditions, particularly in patients who do not respond adequately to conventional therapies. The FDA has recognized some psychedelics as Breakthrough Therapy, with several products currently undergoing clinical trials to assess their safety and efficacy.
This initiative arrives at a time when healthcare costs are escalating, leading many Americans to reconsider their spending in favor of market-driven healthcare solutions. As rising costs persist, analysts warn that this could lead to fewer choices and diminished benefits for plan enrollees.
